Infinity Pharmaceuticals Inc.

780 Memorial Drive
Cambridge
Massachusetts
02139
United States

Tel: 617-453-1000
Fax: 617-453-1001

About Infinity Pharmaceuticals Inc.

The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.
Small molecule discovery and development capabilities Infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.
Strategic alliances Building on its strengths in innovative small molecule drug discovery and development, Infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline.
Business and scientific expertise The company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business and drug discovery and development.
Culture of Citizen-Ownership Infinity’s culture and environment of Citizen-Ownership is as important as its technologies. Infinity works together as a community with the shared goal of bringing important new medicines to patients.

466 articles about Infinity Pharmaceuticals Inc.

Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

8/9/2022

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2022 financial results, unveiled new positive data from the Phase 2 MARIO-275 clinical trial, and provided a business update.
Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast

8/2/2022

Infinity Pharmaceuticals, Inc . will host a conference call on Tuesday, August 9th , 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022.
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference

5/17/2022

Infinity Pharmaceuticals, Inc. announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results

5/3/2022

Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced its first quarter 2022 financial results and provided a corporate update.
Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast

4/26/2022

Infinity Pharmaceuticals, Inc. will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022.
Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 08, 2022

4/8/2022

Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, granted non-statutory stock options to two new employees on April 6, 2022.
Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights

3/29/2022

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2021 financial results and provided corporate highlights.
Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast

3/22/2022

Infinity Pharmaceuticals, Inc. will host a conference call on Tuesday, March 29th, 2022 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2021.
Infinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

3/9/2022

Infinity Pharmaceuticals, Inc. announced that management will be presenting a corporate overview and participating in 1-on-1 meetings in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 16th, 2022.
Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference

1/20/2022

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that it will be highlighted during a virtual oncology fireside chat with B. Riley biotech research analyst Kalpit Patel on Thursday, January 27th at 10:30 am ET.
Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference

1/6/2022

Infinity Pharmaceuticals, Inc. today announced that Adelene Perkins, Chief Executive Officer, will give a corporate presentation at 7:30am ET on January 13, 2022 at the 40th annual J.P. Morgan Healthcare Conference, taking place virtually.
Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance

1/5/2022

Infinity Pharmaceuticals, Inc. today provided an update on eganelisib clinical development plans and 2022 guidance.
Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index

12/14/2021

Infinity Pharmaceuticals, Inc. today announced it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021.
Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat

12/13/2021

Infinity Pharmaceuticals, Inc. today announced that it will be highlighted during a “Best Ideas” virtual fireside chat with B. Riley Biotech research analyst Kalpit Patel on Tuesday, December 14th at 2:30 pm ET.
Clinical Catch-Up: December 6-10

12/13/2021

There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

12/10/2021

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today presented updated data from the ongoing MARIO-3 clinical study during the 2021 San Antonio Breast Cancer Symposium (SABCS).
Biotechs Share Promising Breast Cancer Data at San Antonio Symposium

12/10/2021

The 2021 San Antonio Breast Cancer Symposium is meeting December 7–10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, and virtually.
Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium

12/6/2021

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that it will host an investor event on updated data from the ongoing MARIO-3 clinical study during the San Antonio Breast Cancer Symposium.
Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

11/22/2021

Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update

11/2/2021

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today announced its third quarter 2021 financial results and provided a corporate update on eganelisib, its potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic.